dorsaVi’s clinical product, ViMove, received regulatory clearance from the US Food and Drug Administration (FDA) and Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, in early July.

Regulatory clearance permits ViMove to be sold to and used by healthcare practitioners and their patients throughout the United States and New Zealand.

dorsaVi is now able to launch ViMove in the United States following 510k clearance from the FDA and is already available at MOST clinic, Maryland. Customers in New Zealand can currently access the revolutionary device at Kompass Health Associates in Auckland.

ViMove helps clinicians to objectively assess the individual, identify issues that are unique to each and every patient and, as a result, create more tailored treatment plans.

dorsaVi CEO Andrew Ronchi said, “The United States and New Zealand add to our rapidly expanding number of jurisdictions where ViMove is now available.”

Outside of the US and New Zealand, ViMove is available at medical and allied health clinics in Australia and Europe.